EARN25

Short-Term Volatility Expectations Explode on Sinking Biogen Stock

Bearish analysts have blasted BIIB stock today

Managing Editor
Mar 21, 2019 at 10:32 AM
facebook X logo linkedin


The shares of Biogen Inc (NASDAQ:BIIB) are plunging in today's trading, after the pharma giant and its partner Eisai halted two late-stage Alzheimer's disease drug trials. The decision came after an independent data company said the trials were likely to fail. Considering the drug, aducanumab, had once been projected by Goldman Sachs to reach $12 billion in sales, BIIB is down 27.5% at $232.28, just off a fresh two-year low of $229.11.

Analysts wasted no time reacting to the news. William Blair downgraded BIIB stock to "market perform," while Baird and Piper Jaffray handed out price-target cuts to $250 and $280, respectively. Plus, Cowen and Company slashed its price by 31% to $275. RBC also lowered its BIIB valuation to $240 from $318, calling this a "transformative failure" for Biogen's pipeline. Ahead of today, 14 of 22 covering firms held "buy" or better ratings.

Options traders have been bracing for a pullback. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day put/call volume ratio of 1.57 ranks in the 90th annual percentile, meaning puts have been bought to open over calls at an accelerated clip in recent weeks.

Today, more than 14,500 calls and 9,100 puts have changed hands so far today -- 34 times what's typically seen at this point in the day, and volume pacing in the 100th annual percentile. Short-term volatility expectations have exploded amid today's bear gap, too, with BIIB stock's 30-day at-the-money implied volatility of 37.3% docked in the 88th percentile of its 12-month range.
 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!